Febraayo 12, 2026, Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha ayaa ku dhawaaqday Febraayo 4 in ENHERTU® (trastuzumab deruxtecan) loo soo jeediyay in lagu daro Barnaamijka Daaweynta Degdegga ah si loogu isticmaalo daawaynta dheeraadka ah ee bukaanada qaangaarka ah ee qaba kansarka naasaha hore ee HER2-positive kuwaas oo qaba cudurka faafa ee haraaga ah ka dib daaweynta neoadjuvant anti-HER2. Go'aankani wuxuu ku salaysan yahay xog xiiso leh oo laga helay daraasadda DESTINY-Breast05 Wajiga III, oo lagu soo bandhigay Shirweynihii ESMO ee 2025, kaas oo muujiyay in ENHERTU ay yareysay khatarta dhacdooyinka badbaadada cudurka aan faafin (IDFS) ama dhimashada 53% marka la barbar dhigo T-DM1.
ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki oo keliya Mareykanka) waa ADC oo HER2 ah. Waxaa lagu sameeyay iyadoo la adeegsanayo Tiknoolajiyadda DXd ADC ee gaarka loo leeyahay ee Daiichi Sankyo, ENHERTU waa ADC-ga hormuudka ka ah faylalka kansarka ee Daiichi Sankyo iyo barnaamijka ugu horumarsan ee madal cilmiyeedka ADC ee AstraZeneca. ENHERTU waxay ka kooban tahay antibody monoclonal HER2 oo ku xiran tiro ka mid ah topoisomerase I inhibitor oo lacag ah (oo ah derivative exatecan, DXd) iyada oo loo marayo isku xirayaasha la kala saari karo ee ku salaysan tetrapeptide.
DESTINY-Breast05 waa tijaabo caalami ah, oo xarun badan leh, oo aan kala sooc lahayn, oo furan, oo qiimeynaysa waxtarka iyo badbaadada ENHERTU (5.4 mg/kg) marka la barbar dhigo trastuzumab emtansine (T-DM1) ee bukaanada qaba kansarka naasaha ee hore ee HER2 oo leh cudur faafa oo ku dhaca qanjidhada naasaha ama qanjidhada axillary ka dib daaweynta neoadjuvant iyo khatar sare oo soo noqoshada ah. Khatarta sare ee soo noqoshada waxaa lagu qeexay soo bandhigida kansarka aan la shaqayn karin (kahor daaweynta neoadjuvant) ama qanjidhada axillary ee togan ee cudur ahaan ka dib daaweynta neoadjuvant.
Xog muhiim ah oo laga helay daraasadda DESTINY-Breast05:
- Badbaadada Cudurrada aan Duullaanka ahayn (IDFS): Heerka IDFS ee saddexda sano ah wuxuu ahaa 92.4% gacanta ENHERTU marka la barbar dhigo 83.7% gacanta xakamaynta (T-DM1), taasoo ka dhigan hoos u dhac 53% ah oo ku yimid khatarta (HR=0.47).
- Badbaadada Ka-hortagga Cudurrada (DFS): Heerka DFS ee saddexda sano ah wuxuu ahaa 92.3% gacanta ENHERTU marka la barbar dhigo 83.5% gacanta xakamaynta, taasoo sidoo kale ka tarjumaysa hoos u dhac 53% ah oo ku yimid khatarta (HR=0.47).
- Khatarta Soo Noqnoqoshada Fog (DRFI): Waxaa hoos u dhacay 51%, iyadoo heerarka DRFI ee saddexda sano ah ay yihiin 93.9% marka loo eego 86.1%.
- Khatarta Burburka Maskaxda (BMFI): Waxaa hoos u dhacay 36%, iyadoo heerarka BMFI ee saddexda sano ah ay yihiin 97.6% marka loo eego 95.8%.
Waaxda Caalamiga ah ee Isbitaalka Kansarka ee Koonfurta Magaalada Beijing waxay u heellan tahay inay u adeegto bukaanada dibadda, iyadoo bixinaysa taageero luqado badan leh, biilal toos ah oo caymis caalami ah, la-socod bukaan oo shaqsiyeed, iyo adeegyo la-talin telefon ah. Bukaannada qaba kansarka naasaha ee HER2-positive, Waaxda Caalamigu waxay siisaa koox takhasusyo badan leh oo ah dhakhaatiirta kansarka si ay u horumariyaan qorshayaasha daaweynta ee gaarka ah.
La tasho hadda si aad u hesho qiimeyn daaweyn:
Khadka Tooska ah ee Bukaannada Caalamiga ah: 400-880-3716 (adeegga laba luqadoodlaha ah ee 24-ka saacadood ah, Shiinaha/Ingiriiska)
Khadka Tooska ah ee WeChat: 17801183037
Official Email ①: 100085_010@163.com
Backup Email ②: myimmnet@163.com
Haddii aad tahay bukaan dhawaan la ogaaday oo raadinaya xeelado loogu talagalay cudurrada haraaga ah ka dib daaweynta neoadjuvant, ama bukaan qalliin maray oo ka fiirsanaya qorshe daaweyn oo sii kordhaya, kooxda Waaxda Caalamiga ah waxay si dhakhso ah u dhammaystiri karaan dib u eegis diiwaan caafimaad oo hordhac ah waxayna bixin karaan talooyin daaweyn oo qoran.
Waqtiga boostada: Febraayo-12-2026